NEW YORK — SalioGen Therapeutics said on Wednesday that it has raised $115 million through an oversubscribed and up-sized Series B financing round.
The round was co-led by GordonMD Global Investments and EPIQ Capital Group with participation from new investors Fidelity Management & Research Company, funds and accounts advised by T. Rowe Price Associates, D1 Capital Partners, SymBiosis, the Cystic Fibrosis Foundation, the RD Fund, and others. Existing investor PBM Capital also participated.
SalioGen is developing medicines for inherited diseases based on a technology called exact DNA integration technology, or EDIT, which uses a mammal-derived enzyme called saliogase to integrate DNA into defined locations in the genome. The company's pipeline includes early-stage preclinical programs in a range of eye, lung, liver, heart, and kidney disorders.
Cambridge, Massachusetts-based SalioGen said that it will use the newly raised cash to continue work on its therapeutic platform, expand its staff, and establish manufacturing and automation capabilities.